472-P: Online Patient Education on GLP-1 Receptor Agonists in Patients with T2D and CVD Prompts Real-Life Changes

We sought to measure the impact of online education for patients on knowledge, confidence, and prompting change in daily life. Two educational activities were available online, comprised of text and integrated visuals as well as either a patient or clinician video. Demographic questions were asked prior to starting the education. A knowledge question was asked both before and after the activity to assess learning gains, as well as intent to change and confidence questions at the end. Absolute improvements were calculated for pre/post questions. The activities launched in August, 2020, and preliminary data collected through November, 2020. Activity 1: To date, 28,983 learners have participated in the patient/caregiver activity, “How is Diabetes Related to Heart Disease?” Of which, 4,912 completed all questions (included in outcomes analysis): 51% male; 51% white, non-Hispanic; 66% over the age of 54; 71% have diabetes, 18% were interested in learning more about diabetes and heart disease. Intent-to-act: 85% plan to talk to their HCP about their risk for heart disease. Confidence changes: 87% reported increased confidence talking to my doctor or healthcare provider about how to lower their risk for heart disease. Activity 2: To date, 40,812 learners have participated in the patient/caregiver activity, “How Can I Make my Heart Healthier and Control my Sugar Better at the Same Time?” Of these, 10,233 completed all questions (included in outcomes analysis): 52% female; 53% white, non-Hispanic; 66% over the age of 54; 69% have diabetes, 22% were interested in learning more about ways to treat diabetes and heart disease. Knowledge changes: 54% improvement in recognizing GLP-1 RAs can treat T2D and lower the risk for heart disease (12% pre to 66% post). The metrics and outcomes gathered in this assessment are a strong indicator that these patient-focused online educational activities improved knowledge, confidence, and prompted intent to act by patients related to T2D and CVD risk reduction. Disclosure A. Larkin: None. A. Le: None. Funding Novo Nordisk